Impact of biochemical failure classification on clinical outcome: a secondary analysis of Radiation Therapy Oncology Group 9202 and 9413.
作者： Daniel A. Hamstra , Kyounghwa Bae , Gerald Hanks , Chen Hu , William U. Shipley
DOI: 10.1002/CNCR.29146
关键词: Medicine 、 PSA Failure 、 Radiation therapy 、 Secondary analysis 、 Internal medicine 、 Oncology 、 Biochemical failure
摘要: BACKGROUND Biochemical failure (BF) after radiation therapy is defined on the basis of a rising prostate-specific antigen (PSA) level (A1 failure) or any event that prompts initiation salvage androgen-deprivation without PSA (A2). It was hypothesized A2 may have different prognosis.
elsevier.com
sci-hub.se 参考文章(24)
Fabio L. Cury, Daniel Hunt, Mack Roach, William Shipley, Elizabeth Gore, I-Chow Hsu, Robert E. Krisch, Michael J. Seider, Howard Sandler, Colleen Lawton, Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413 Cancer. ,vol. 119, pp. 1999- 2004 ,(2013) , 10.1002/CNCR.28019
E. L. Kaplan, Paul Meier, Nonparametric Estimation from Incomplete Observations Springer Series in Statistics. ,vol. 53, pp. 319- 337 ,(1992) , 10.1007/978-1-4612-4380-9_25
Nirav S. Kapadia, Karin Olson, Howard M. Sandler, Felix Y. Feng, Daniel A. Hamstra, Interval to biochemical failure as a biomarker for cause-specific and overall survival after dose-escalated external beam radiation therapy for prostate cancer. Cancer. ,vol. 118, pp. 2059- 2068 ,(2012) , 10.1002/CNCR.26498
James W Denham, Allison Steigler, Chantelle Wilcox, David S Lamb, David Joseph, Chris Atkinson, John Matthews, Keen-Hun Tai, Nigel A Spry, David Christie, Paul S Gleeson, Peter B Greer, Catherine D'Este, Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial Lancet Oncology. ,vol. 9, pp. 1058- 1068 ,(2008) , 10.1016/S1470-2045(08)70236-5
M. Roach, M. DeSilvio, C. Lawton, V. Uhl, M. Machtay, M.J. Seider, M. Rotman, C. Jones, S.O. Asbell, R.K. Valicenti, S. Han, C.R. Thomas, W.S. Shipley, Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. Journal of Clinical Oncology. ,vol. 21, pp. 1904- 1911 ,(2003) , 10.1200/JCO.2003.05.004
Mark Shilkrut, P. William McLaughlin, Gregory S. Merrick, Jeffrey M. Vainshtein, Felix Y. Feng, Daniel A. Hamstra, Interval to Biochemical Failure Predicts Clinical Outcomes in Patients With High-Risk Prostate Cancer Treated by Combined-Modality Radiation Therapy International Journal of Radiation Oncology Biology Physics. ,vol. 86, pp. 721- 728 ,(2013) , 10.1016/J.IJROBP.2013.03.028
Jason P. Fine, Robert J. Gray, A Proportional Hazards Model for the Subdistribution of a Competing Risk Journal of the American Statistical Association. ,vol. 94, pp. 496- 509 ,(1999) , 10.1080/01621459.1999.10474144
Mack Roach, Carol Marquez, Hae-Sook Yuo, Perinchery Narayan, Lorie Coleman, Unyime O. Nseyo, Zarrin Navvab, Peter R. Carroll, Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and gleason score in men with clinically localized prostate cancer International Journal of Radiation Oncology*Biology*Physics. ,vol. 28, pp. 33- 37 ,(1994) , 10.1016/0360-3016(94)90138-4
Robert J. Gray, A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk Annals of Statistics. ,vol. 16, pp. 1141- 1154 ,(1988) , 10.1214/AOS/1176350951
Skyler B. Johnson, William C. Jackson, Jure Murgic, Felix Y. Feng, Daniel A. Hamstra, Time to Nadir PSA: Of Popes and PSA--The Immortality Bias. American Journal of Clinical Oncology. ,vol. 38, pp. 465- 471 ,(2015) , 10.1097/COC.0B013E3182A468B2